Effect of antiviral treatment on evolution of liver steatosis in patients with chronic hepatitis C: indirect evidence of a role of hepatitis C virus genotype 3 in steatosis. (11th February 2004)

• Record Type: Journal Article
• Authors: Castéra, L; Hézode, C; Roudot-Thoraval, F; Lonjon, I; Zafrani, E-S; Pawlotsky, J-M; Dhumeaux, D
• Is Part Of: Gut. Volume 53:(2004)Supplement 3
• Page Start: 420
• Page End: 424
• Publication Date: 2004-02-11
• Subjects: chronic hepatitis C -- steatosis -- interferon -- hepatitis C virus genotype 3; HCV, hepatitis C virus -- SVR, sustained virological responders -- NR, non-responders -- BMI, body mass index -- ALT, alanine aminotransferase -- MU, million units -- OR, odds ratio; Gastroenterology -- Periodicals; 616.33
• DOI: 10.1136/gut.2002.009936
• Languages: English
• ISSNs: 0017-5749

Abstract

Abstract : Background and aim: Recent studies suggest that liver steatosis in chronic hepatitis C may be the expression of a direct cytopathic effect of hepatitis C virus (HCV), particularly in patients infected with genotype 3. To investigate this hypothesis, we studied the relationship between steatosis evolution and HCV clearance after antiviral treatment in patients with chronic hepatitis C and paired liver biopsies. Methods: A total of 151 patients (37 with HCV genotype 3; 114 with HCV non-3 genotypes) were selected according to the following criteria: presence of steatosis at initial biopsy; no antiviral treatment prior to the first biopsy; antiviral treatment received between the two biopsies; body mass index (BMI) <28 kg/m 2 ; absence of excessive alcohol intake; no serum hepatitis B surface antigen or human immunodeficiency virus antibodies; and absence of diabetes mellitus. Evolution of steatosis was examined by comparing steatosis grades between the two biopsies. Results: Twenty five patients (16.5%) were sustained virological responders (SVR) to antiviral treatment. Steatosis evolution after antiviral treatment was as follows: improvement in 36% of cases; stability in 51%; and worsening in 13%. Steatosis improvement was significantly more frequent in SVR than in non-responders (NR) (64% v 31%; p<0.004). This significant difference occurred in patients infected with genotype 3 (91% v 19%; p<0.0001) but not in those infected with non-3 genotypes (43% v 34%; NS). Among the 25 SVR, improvement in steatosis was significantly more frequent in patients infected with genotype 3 than in those infected with non-3 genotypes (91% v 43%; p<0.04) whereas in NR, improvement in steatosis did not differ between those infected with genotype 3 and non-3 genotypes (19% v 34%; NS). In multivariate analysis, four factors were independently associated with steatosis improvement: sustained virological response to antiviral therapy (odds ratio (OR) 6.06 (95% confidence interval (CI) 1.61–22.9); p = 0.01), severe steatosis (OR 5.50 (95% CI 1.54–19.6); p = 0.01), HCV genotype 3 (OR 2.90 (95% CI 0.85–10.0); p = 0.07), and BMI >25 kg/m 2 (OR 0.24 (95% CI 0.08–0.73); p = 0.02). Conclusions: Our results showed significant improvement in steatosis in patients infected with HCV genotype 3, who achieved sustained viral clearance. This provides further evidence for direct involvement of HCV genotype 3 in the pathogenesis of hepatic steatosis.